I have been extremely surprised in the almost total lack of interest in this company despite its’ surprising accomplishments to date. The share price has been hovering on or about the mid .40c mark for a considerable time.
I note that on the release of a positive news item the share price may rise a penny or two and the share volume jumps exponentially, however by the end of the day the price is back either to its’ initial start or even slightly below. This happens not once or twice but on the release of practically every positive piece of news.
Now I am aware that the Venture Exchange has a reputation that, if I am generous, could be called ignoble, its’ catchall name, the Vulture Exchange covers it quite well.
I copied the following from Equedia which seems to fit with the Theralase situation. They are referring to the lack of uptick.
companies trying to raise money at higher prices to hire more staff or move their projects forward, this rule change can cripple them – especially under the liquidity constraints of the Canadian market.
It doesn’t take a lot of money to control a stock via short selling on the TSX Venture.
As a matter of fact, institutions often hammer stocks via short selling and back up their shorts with warrants they obtained in a previous financing. They often force the price of a stock down to finance the same companies they’re shorting to get a better financing price, or to force a company into a financing arrangement.”
Following are a number of positive NRs covering the past year, I find them quite impressive and can be checked on their website.
eptember 19, 2017
Theralase Demonstrates 24 Month Stability of Lead Anti-Cancer Drug
September 18, 2017
Theralase Theralase Demonstrates Increased Efficacy for Latest Anti-Cancer Drug
September 12, 2017
Theralase Anti-Cancer Drugs Effective in the Destruction of Cervical Cancer
September 05, 2017
Theralase Anti-Cancer Drugs Independently Verified and Validated
August 22, 2017
Theralase Anti-Cancer Technology Effective for the Destruction of Lung Cancer
August 08, 2017
Theralase PDT Technology Used to Treat Fourth Patient for Bladder Cancer
August 01, 2017
Theralase Achieves Exploratory Endpoint of Efficacy for Anti-Cancer Technology
July 25, 2017
Theralase Technology Proven Effective for the Treatment of Arthritis
June 29, 2017
Theralase Researcher Granted Second US Patent for Novel Anti-Cancer Drugs
June 26, 2017
Theralase Presents Phosphorescent Photosensitizers at International World Congress
June 15, 2017
Theralase Presents X-Ray Activation at International World Congress
June 14, 2017
Theralase Presents Dosimetry Planning at International World Congress
June 13, 2017
Theralase Successfully Achieves Primary and Secondary Objectives for First Three Patients Treated Using Anti-Cancer Technology for Bladder Cancer
May 26, 2017
123…7Next »Theralase PDT Technology Used to Treat Third Patient for Bladder Cancer
April 20, 2017
Theralase PDT Technology Used to Treat Second Patient for Bladder Cancer
April 18, 2017
Theralase Affiliated Researchers to Present at International Conference
April 12, 2017
Theralase Announces Acceptance of Peer Reviewed Publication for Next Generation Anti-Cancer Drugs
April 06, 2017
Theralase PDT Technology Used to Treat First Patient for Bladder Cancer
April 04, 2017
Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug
March 15, 2017
Theralase Releases AGM Presentation Video
December 14, 2016
Theralase Demonstrates 12 Month Stability of Lead Anti-Cancer Drug
November 30, 2016
Theralase Increases GBM Brain Cancer Survival by 925%
October 28, 20
I have been told by various people that Canadian Exchanges are considered a bit of a joke, someone else claimed that it wasn’t the exchanges that were a joke, it was the regulatory procedures or lack of when it comes to the retail investor, however far be it for me to be judgemental.